Enclomiphene Citrate Legal & Patent Challenges

Why Enclomiphene Never Reached FDA Approval

Enclomiphene citrate is the trans-isomer of clomiphene, isolated specifically because it raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH) without the estrogenic agonist effects of the cis-isomer (zuclomiphene). Repros Therapeutics developed it under the brand name Androxal for secondary hypogonadism in overweight men with low testosterone. The FDA issued a complete response letter (CRL) in December 2015 citing deficiencies in the analytical chemistry package and concerns about lot-to-lot variability in the drug substance 1.

A second CRL followed in 2016. The agency requested additional manufacturing data and raised questions about the adequacy of the safety database for chronic use. Repros Therapeutics, already financially strained after years of development, could not fund another round of studies. The company pivoted away from enclomiphene entirely. No other sponsor has filed an NDA since.

The result is a drug with Phase III efficacy data, a well-characterized mechanism, and no legal pathway to branded market access. Kim et al. (2016) demonstrated that enclomiphene 25 mg daily normalized morning testosterone in 73.3% of hypogonadal men over 16 weeks while preserving spermatogenesis, a finding that exogenous testosterone cannot match 1.

The Patent Situation After Repros

Repros Therapeutics held multiple patents covering enclomiphene formulations and methods of use for treating hypogonadism. The composition-of-matter patents (US 6,911,468 and related filings) began expiring in the early 2020s. Method-of-use patents covering specific dosing regimens for secondary hypogonadism extended slightly longer, but without an approved product on the market, enforcement became impractical.

Patent expiration without FDA approval created an unusual situation. Generic manufacturers had no reference listed drug to file an ANDA against. Branded sponsors had no exclusivity incentive to pursue a new NDA. The economic calculus that normally drives drug development collapsed. A sponsor filing today would face full NDA costs (estimated $50-100 million for the remaining studies) with no guarantee of market exclusivity beyond any new formulation patents they might file.

This vacuum is precisely why compounding pharmacies stepped in. Without an approved branded product, enclomiphene citrate exists in a regulatory gray zone where 503B outsourcing facilities can legally compound it from bulk drug substance, provided they meet certain conditions under Section 503B of the Federal Food, Drug, and Cosmetic Act 2.

FDA's Position on Compounded Enclomiphene

The FDA maintains that compounded drugs are not FDA-approved and do not undergo premarket review for safety, efficacy, or quality. The agency's position on enclomiphene compounding specifically has been one of enforcement discretion rather than explicit prohibition. Enclomiphene citrate does not appear on the FDA's "Difficult to Compound" list, nor has it been placed on the bulk drug substances withdrawal list under 503B review as of May 2026.

Section 503B of the FD&C Act permits outsourcing facilities to compound without individual prescriptions if they register with the FDA, comply with current good manufacturing practice (cGMP) requirements, and report adverse events 3. The FDA has conducted inspections of facilities compounding enclomiphene and issued Form 483 observations related to sterility and potency testing, but has not taken broad enforcement action against the compound itself.

This regulatory posture could shift. The FDA Compounding Quality Center has been progressively tightening oversight of 503B facilities since 2020. If a safety signal emerged from compounded enclomiphene (contamination, supraphysiologic hormone levels from dosing errors, or hepatotoxicity reports), the agency could move to restrict access rapidly.

Clinical Evidence Supporting the Regulatory Debate

The irony of enclomiphene's regulatory position is that its clinical evidence base is stronger than many approved SERMs for male indications. Three Phase III trials (ZA-301, ZA-302, ZA-304) enrolled over 1,000 men with secondary hypogonadism and demonstrated consistent testosterone normalization with preservation of sperm parameters 1.

Kim et al. reported in BJU International that enclomiphene 12.5 mg and 25 mg daily produced mean testosterone increases from approximately 220 ng/dL at baseline to 430-450 ng/dL at 16 weeks. Sperm concentration remained stable or increased, contrasting sharply with testosterone replacement therapy, which suppresses spermatogenesis to azoospermia in 65% of men within 6 months 1.

The Endocrine Society's 2018 guidelines on male hypogonadism acknowledge SERMs as an option for men who wish to preserve fertility but stop short of recommending enclomiphene specifically, citing the absence of FDA approval 4. Dr. Bradley Anawalt, then-president of the Endocrine Society, stated in the guideline commentary: "Off-label clomiphene use is common but not supported by the same level of evidence as testosterone replacement." This statement predated the full publication of enclomiphene Phase III results, which arguably met a higher evidentiary bar than what existed for clomiphene at that time.

The American Urological Association's 2018 guidelines on testosterone deficiency similarly note that SERMs can be considered in men desiring fertility, with clomiphene citrate receiving the most clinical attention 5.

Legal Challenges From Multiple Directions

Three distinct legal pressures shape enclomiphene's current status. First, the question of whether bulk enclomiphene citrate qualifies as a "component" of an FDA-approved drug. Clomiphene citrate (Clomid) is FDA-approved for female ovulatory dysfunction. Enclomiphene is the trans-isomer component of that racemic mixture. Some legal analyses argue this creates a pathway for compounding under the "component of an approved drug" provision, while others contend that an isolated isomer constitutes a distinct molecular entity requiring its own approval.

Second, state pharmacy boards have taken varying positions. Some states (notably Texas, Florida, and California) have allowed compounding pharmacies to dispense enclomiphene with a valid prescription and appropriate documentation. Others have issued advisory opinions questioning its legality. This patchwork creates compliance uncertainty for telehealth platforms operating across state lines.

Third, the Federal Trade Commission has scrutinized marketing claims made by clinics dispensing compounded enclomiphene. Claims that it is "FDA-approved" or "equivalent to Androxal" have drawn warning letters. Clinics must distinguish between "compounded per physician order" and "FDA-approved," a distinction patients often do not understand 6.

Safety Considerations Without Post-Market Surveillance

An FDA-approved drug benefits from structured pharmacovigilance: REMS programs, MedWatch reporting, and FDA Sentinel system monitoring. Compounded enclomiphene exists outside this infrastructure. Adverse events may go unreported or be attributed to "testosterone therapy" broadly in electronic health records.

The known safety profile from Phase III trials showed enclomiphene to be well tolerated. Headache (5.2%), nausea (3.1%), and hot flashes (2.8%) were the most common adverse events, with discontinuation rates below 4% across all trials 1. Liver enzyme elevations occurred in 1.4% of subjects, all Grade 1, and resolved without intervention.

Long-term safety data beyond 12 months does not exist from controlled trials. The theoretical concern with chronic SERM use in men (venous thromboembolism, visual disturbances, bone density changes) derives primarily from tamoxifen and raloxifene data in women. Whether these risks extrapolate to enclomiphene at 12.5-25 mg daily in men remains unknown. A 2019 systematic review of clomiphene use in men found no increase in thromboembolic events across 16 studies, though follow-up periods were generally short 7.

The Compounding Market Reality

Despite regulatory ambiguity, compounded enclomiphene has become one of the most commonly prescribed SERMs in men's health clinics. 503B outsourcing facilities report it among their top 20 compounds by volume. Telehealth platforms specializing in testosterone optimization have made it a cornerstone offering, positioning it as a fertility-preserving alternative to testosterone cypionate injections.

Pricing varies significantly. Compounded enclomiphene capsules (25 mg, 30-day supply) range from $30 to $150 depending on the pharmacy and platform markup. This compares to approximately $15-40 for generic clomiphene (Clomid) 50 mg tablets, though clomiphene carries the estrogenic side effects of the zuclomiphene isomer that enclomiphene was specifically designed to avoid.

Quality control is the primary clinical concern. Without FDA cGMP oversight at the same standard as commercial manufacturers, potency variation between compounding pharmacies can be substantial. A 2022 analysis of compounded hormone preparations found that 15-25% of tested samples fell outside the stated potency range of plus or minus 10% 8. Whether this applies specifically to enclomiphene preparations has not been studied, but the risk is non-trivial.

What Would It Take for FDA Approval Now

A new NDA for enclomiphene would require a sponsor willing to invest in: (1) a new drug substance manufacturer meeting current FDA standards, (2) a confirmatory Phase III trial with at least 12 months of safety follow-up (per FDA guidance on testosterone therapies issued in 2015), (3) a cardiovascular outcomes study or at minimum a pre-specified MACE analysis, given the FDA's 2015 labeling requirement for exogenous testosterone products, and (4) a REMS or medication guide addressing off-label use risks.

The 2015 FDA guidance requiring cardiovascular safety data for testosterone products created an open question: does it apply to SERMs that raise endogenous testosterone? The FDA has not clarified this point. A prudent sponsor would likely include cardiovascular endpoints preemptively.

Some industry observers have speculated that a 505(b)(2) pathway could reduce costs by referencing the existing clomiphene (Clomid) NDA and the published Phase III data. This would still require bridging studies to demonstrate bioequivalence between the proposed product and the clinical trial material, plus whatever additional safety data the FDA demands 9.

The commercial viability question is stark. With compounding pharmacies already serving the market at low cost and no patent exclusivity available, a sponsor would need to demonstrate sufficient branded product advantages (insurance coverage, physician confidence, standardized potency) to justify the investment. No sponsor has publicly indicated interest as of 2026.

Implications for Prescribing Clinicians

Clinicians prescribing compounded enclomiphene should document informed consent explicitly noting: the drug is not FDA-approved, quality may vary between pharmacies, long-term safety data beyond 12 months is limited, and the patient accepts these uncertainties. The American Association of Clinical Endocrinology (AACE) recommends that prescribers verify their compounding pharmacy's 503B registration status and most recent FDA inspection results before ordering 10.

Monitoring protocols should include baseline and quarterly testosterone, LH, FSH, estradiol, hematocrit, and liver function tests. Any patient developing visual symptoms (blurring, scotomata, phosphenes) should discontinue immediately pending ophthalmologic evaluation, consistent with SERM class labeling for clomiphene 5.

Prescribers in states with restrictive pharmacy board positions should confirm that their state permits dispensing of compounded enclomiphene and that their malpractice coverage extends to non-FDA-approved compounded preparations. Several malpractice carriers have added exclusions or surcharges for clinics whose revenue derives primarily from compounded hormones.